Giampaolo Bianchini

📢1/10 Out on @Nature our work ‘Spatial predictors of immunotherapy response in triple-negative breast cancer’ rdcu.be/dluy0 lead by @HRazaAliLab and myself 👉To work, immunotherapy requires certain immune cell types, in proper functional state and spatial context 🧵👇

The PATINA study coordinated in Italy by Fondazione Michelangelo, shows that adding palbociclib to standard therapy improves progression-free survival in hormone receptor-positive and HER2-positive metastatic breast cancer patients fondazionemichelangelo.org/news-update/pa… #BreastCancer #Oncology

📣 #ESMOBreast26: Your participation is pivotal in shaping the future of breast cancer care. Here, you will discover ground-breaking studies from globally recognized experts in the field. ⏰ Register by 8 April for advantageous fees 🔗 ow.ly/hzv650YBbet #esmomeetings

X mi ricorda che mi sono iscritto oggi 7 anni fa per rimanere informato e postare il lavoro del mio laboratorio a NYC. Poi X è diventato uno strumento per fare divulgazione amatoriale. Ho conosciuto molte persone interessanti. Ho aiutato qualcuno e qualcuno ha aiutato me. Grazie!

🚨 REGISTRATION NOW OPEN – JOIN FROM ANYWHERE 🌍 🧬 Gulf of Naples Breast Cancer Conference 2026 📅 May 4–5, 2026 📍 Live from Ravello, Italy 🇮🇹 💻 Available in LIVE STREAMING Join leading international experts in oncology for a high-level scientific program focused on: ✔️ Precision Oncology ✔️ Targeted Therapies ✔️ Immunotherapy ✔️ Translational Research 🎯 Designed for oncologists, researchers, and healthcare professionals worldwide ✨ Why attend online? 🔹 Access top-tier international faculty 🔹 Stay updated on the latest clinical advances 🔹 Engage in a global scientific discussion 🔹 Attend from anywhere ⚠️ Limited virtual access available 👉 Secure your spot now gon2026.andromedae20.com fb.watch/G6fsgrHGAM/ via @FacebookWatch

impressive data in #SCLC26 on IZA-BREN ( EGFRxHER3 ADC) with ICI surplulimab in 1L ES-SCLC: ➡️ ORR 85-92%! across IZABREN doses ➡️ mDOR =7-8 m ➡️ Discontinuation due to TRAEs only 7.3% Dawn 🌅 of a carbo-Etop- free 1L treatment in SCLC? @myESMO @IASLC

Results from the phase 2 PRADO trial show favorable 5-years outcomes in overall survival with adjuvant ipilimumab plus nivolumab in stage III macroscopic melanoma fondazionebonadonna.org/en/neoadjuvant… #FondazioneBonadonna #Oncology #CancerResearch @BianchiniGP @CarmenCriscit @mauricallari

Oggi è il quinto anniversario della morte del mio mentore. Ho lavorato con lui 15 anni e mi ha cambiato la vita. Era un visionario, durissimo, ambizioso, che credeva e scommetteva sui giovani. Io fui uno di quelli. Oggi molti farmaci si devono anche a lui. Que te sea leve, José

The 4 biomarkers to meaningfully assess a person's risk of coronary artery disease @rayshafarah @aklfahed @pnatarajanmd @JACCJournals @uk_biobank sciencedirect.com/science/articl…

Clinical benefits on disease-free survival and overall survival with the addition of carboplatin to adjuvant epirubicin/cyclophosphamide followed by taxanes in early-stage triple-negative breast cancer fondazionemichelangelo.org/news-update/ad…… #FondazioneMichelangelo #Oncology #CancerResearch

FOURLIGHT-1: Ph II study of fulvestrant + atirmociclib (CDK4 selective inhib) vs fulvestrant or everolimus + exemestane is positive, with HR 0.6. Great news, as this novel CDK4i seems very well tolerated! @antgiorda businesswire.com/news/home/2026…

New #JITC review: TCR sequencing in cancer immunology and immunotherapy: what, when, where, why, and how jitc.bmj.com/content/14/3/e…

In mBC, not all imaging changes mean your therapy has stopped working and switching too early is a real risk. 1/ RECIST 1.1 sets a clear bar for progression: ≥20% increase in the sum of target lesion diameters (with ≥5mm absolute increase), unequivocal progression of non-target lesions, or new lesions. Not every change on imaging meets this threshold. 2/ Three scenarios commonly and incorrectly flagged as progression: new asymptomatic sclerotic bone lesions, small mm asymptomatic changes in known lesions, and increased SUV on PET without corresponding size change. None of these, in isolation, trigger a therapy switch for me. 3/ Sclerotic bone lesions deserve particular attention. When effective therapy kills tumor cells in bone, the body lays down new bone matrix appearing dense and white on CT. This is a healing response, not new disease. 4/ The consequences of switching too early are real: loss of disease control from a working regimen, premature exhaustion of sequencing options. 5/ My approach: I integrate clinical symptoms, tumor markers, and serial scans together before making any decision to change therapy. 6/ Bottom line: confirm true progression before changing course. When in doubt, a short interval rescan is almost always preferable to an unnecessary switch. #BreastCancer #MedOnc

A single dose of antibiotics can have lasting effects on your gut microbiome, with changes that last well beyond 4 years. Three types of antibiotics stood out for their long term disruptive impact (3 at left, Figure) @NatureMedicine nature.com/articles/s4159…

Preventing HER2 degradation improves efficacy of trastuzumab deruxtecan (TDXd). doi.org/10.1038/s43018… - Silencing of FBXL2 leads to increased HER2 expression on the plasma membrane and sensitizes HER2-0 TNBC cells to T-DXd treatment. - Targeted inhibition of FBXL2 with ketoconazole (KCZ) encapsulated into LNPs prevents proteosome mediated degradation of HER2, resulting in increased HER2 expression, most notably on IHC 0 or HER2-low breast cancer cells @OncoAlert @PTarantinoMD

📣 #ESMOBreast26: Collaborations between experts of different countries and areas of expertise, excellent networking opportunities and the latest science and education. ⏰Register by 8 April for advantageous fees. 🔗 ow.ly/HWHU50YrNZv #esmomeetings

@curijoey @LaStatale @IEOufficiale @myESMO @ComuneMI Grande @curijoey !

Milano mi ha dato tutto: opportunità, incontri, sfide. Grazie Milano per ciò che sono diventato e grazie al Corriere della Sera per aver raccontato questo legame inserendomi tra i 150 italiani che testimoniano la sua storia. Un onore che porterò con me @LaStatale @IEOufficiale

Fondazione Umberto Veronesi esprime grande soddisfazione per il conferimento del Premio “Eccellenza Donna”, promosso dalla Senatrice Cinzia Pellegrino, alla sua VI edizione, al Direttore Generale Monica Ramaioli, riconoscimento assegnato dal Senato a… fondazioneveronesi.it/news/il-premio…

We show that gBRCA2 is associated with significantly shorter PFS on CDK4/6i-ET. The signal holds in the 1st-line setting, across all treatment lines, and in an independent external validation cohort (FLATIRON) (6/n)

Metastasis kills most cancer patients and grows from invisible seeds. How do these seeds escape from attack by immune cells? These seeds harness stress hormones!🤯 ⁦thanks to ⁦@nyscf⁩ ⁦@parkerici⁩ for their support. Today at ⁦@Nature⁩ nature.com/articles/s4158…

So excited to share our latest work with @PedramRazaviMD, @MSKCancerCenter, and Sarat Chandarlapaty out today in @Nature. nature.com/articles/s4158… (1/n)